Abstract
BackgroundSheng-Mai Yin (SMY), a modern Chinese formula based on Traditional Chinese Medicine theory, has been used to treat cardiovascular diseases in Eastern Asia. Our study focuses on the cardioprotection of SMY against doxorubicin (DOX)-induced cardiac toxicity in vivo.MethodsRats were injected with DOX (2.5 mg/kg) in six injections over a 2-week period. SMY was administrated intragastrically at the dose of 8.35, 16.7 and 33.4 g/kg, or 16.7 g/kg only twice a day concurrently with DOX for the 2-weeks. A series of assays were performed to detect the effects of SMY on: (i) heart weight index (HWI) and left ventricular mass index (LVMI); (ii) cardiac function; (iii) heart tissue morphology; (iv) the contents of carboxy terminal propeptide of procollagen typeI (PICP), amino terminal propeptide of procollagen type III (PШNP), transforming growth factor-β1 (TGF-β1), B-type natriuretic peptide (BNP), monocyte chemoattractant protein-1 (MCP-1), interferon gamma (INF-γ) and interleukin 6 (IL-6) by ELISA; (v) the mRNA levels of TGF-β1 and toll-like receptor-2 (TLR2); and (vi) protein level of TGF-β1.ResultsRats treated with SMY displayed the reductions of BNP and CK-MB increased by DOX in a dose-dependent manner. Moderate dose of SMY exhibited the correction for the increased HWI, LVMI, and the injured cardiac function, as well as the collagen accumulation. In addition, cardioprotection of SMY against DOX-induced cardiac toxicity was demonstrated by the reduction of myocardial fibrosis, characterized by the suppression of PICP, PШNP and TGF-β1, as well as the anti-inflammation and the regulation for cardiac immune microenvironment, characterized by the inhibition of TLR2, MCP-1, INF-γ and IL-6.ConclusionsSMY may protect heart function through the restriction of myocardial fibrosis induced by DOX, which suggests the potentially therapeutic effect of SMY on DOX-induced cardiomyopathy.
Highlights
Sheng-Mai Yin (SMY), a modern Chinese formula based on Traditional Chinese Medicine theory, has been used to treat cardiovascular diseases in Eastern Asia
Treatment with SMY with low, moderate and high dose significantly inhibited the level of B-type natriuretic peptide (BNP) in a dos -dependent manner (Fig. 1a, P < 0.05 or P < 0.01), with the reduction of 16.29 %, 23.28 % and 33.97 % respectively
After the treatment for 2 weeks by SMY, heart weight index (HWI) and left ventricular mass index (LVMI) were respectively recovered to 3.49 ± 0.145 mg/g and 2.67 ± 0.21 mg/g, with a statistical significance (P
Summary
Sheng-Mai Yin (SMY), a modern Chinese formula based on Traditional Chinese Medicine theory, has been used to treat cardiovascular diseases in Eastern Asia. Doxorubicin (DOX), a broad spectrum anthracycline antineoplastic, is widely used for the treatment of various malignancies such as acute leukemia, lymphoma and breast cancer [1, 2]. Clinical applicationsof this drug are restricted due to the severe, dose-dependent, acute cardiotoxicity that may involve various signaling pathways including free radical generation, peroxynitrite. Anti-apoptosis effect of Shengmai injection was observed in DOXinduced rats, characterized by the reduction of Bax protein and the increase of Bcl-2 protein [16] It seemed that Shengmai treatment had an effect in DOXinduced cardiac toxicity model. The rat models induced by DOX were employed and many pharmacological indicators including electrocardiogram, cardiac function and myocardial fibrosis analysis were observed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
